ValuEngine upgraded shares of Catabasis Pharmaceuticals (NASDAQ:CATB) from a hold rating to a buy rating in a research note published on Monday.
Several other equities research analysts have also issued reports on CATB. Zacks Investment Research lowered shares of Catabasis Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Tuesday, October 9th. Oppenheimer set a $70.00 target price on shares of Catabasis Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, November 14th. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus target price of $30.63.
Shares of CATB stock traded up $0.23 on Monday, hitting $5.45. The company’s stock had a trading volume of 937 shares, compared to its average volume of 128,963. Catabasis Pharmaceuticals has a fifty-two week low of $3.60 and a fifty-two week high of $23.80. The firm has a market cap of $35.31 million, a PE ratio of -0.42 and a beta of 1.20.
Catabasis Pharmaceuticals (NASDAQ:CATB) last released its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.60) by $0.80. Sell-side analysts anticipate that Catabasis Pharmaceuticals will post -4.8 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Catabasis Pharmaceuticals stock. BlackRock Inc. boosted its position in shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) by 140.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 170,293 shares of the biotechnology company’s stock after acquiring an additional 99,348 shares during the period. BlackRock Inc. owned 0.24% of Catabasis Pharmaceuticals worth $136,000 at the end of the most recent quarter.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases.
Recommended Story: Asset Allocation Models, Which is Right For You?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.